1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity

[Image: see text] Early antiviral treatments, including intravenous remdesivir (RDV), reduce hospitalization and severe disease caused by COVID-19. An orally bioavailable RDV analog may facilitate earlier treatment of non-hospitalized COVID-19 patients. Here we describe the synthesis and evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlin, Aaron F., Beadle, James R., Clark, Alex E., Gully, Kendra L., Moreira, Fernando R., Baric, Ralph S., Graham, Rachel L., Valiaeva, Nadejda, Leibel, Sandra L., Bray, William, McMillan, Rachel E., Freshman, Jonathan E., Garretson, Aaron F., McVicar, Rachael N., Rana, Tariq, Zhang, Xing-Quan, Murphy, Joyce A., Schooley, Robert T., Hostetler, Karl Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108740/
https://www.ncbi.nlm.nih.gov/pubmed/37040439
http://dx.doi.org/10.1021/acs.jmedchem.3c00046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108740/
https://www.ncbi.nlm.nih.gov/pubmed/37040439
http://dx.doi.org/10.1021/acs.jmedchem.3c00046

Ejemplares similares